Flexible MoS2‐Embedded Human Serum Albumin Hollow Nanocapsules with Long Circulation Times and High Targeting Ability for Efficient Tumor Ablation

Abstract Herein, MoS 2 ‐embedded human serum albumin hollow nanocapsules (denoted MoS 2 /HSA) are successfully prepared via a hard‐core‐assisted layer‐by‐layer coating approach. The hollow MoS 2 /HSA nanocapsules possess an uniform size (280 nm), a larger hollow cavity, a low Young's modulus (222 ± 20 MPa), excellent photothermal conversion ability, and a high drug loading capacity for doxorubicin (27 wt%). The flexible hollow MoS 2 /HSA nanocapsules exhibit significantly enhanced cellular uptake efficiency against breast cancer cells duo to their flexible property and targeting ability of HSA. In vivo experiments show that the flexible MoS 2 /HSA could reduce phagocytosis and effectively improve blood persistence and tumor accumulation. In vitro and in vivo experiments have demonstrated that the flexible MoS 2 /HSA based nanoplatforms effectively ablate breast cancer cells via synergistic photothermal and chemical therapy.